# Drug Development Core Shared Resource

> **NIH NIH P30** · UNIVERSITY OF WISCONSIN-MADISON · 2021 · $219,105

## Abstract

PROJECT SUMMARY / ABSTRACT 
The mission of the Drug Development Core (DDC) is to make state-of-the-art drug development accessible 
and affordable to UWCCC members. Development of innovative therapies is a priority area of research in the 
UWCCC Strategic Plan, and drug development requires specialized expertise in synthetic, computational, and 
analytical chemistry. The overarching scientific discipline in the DDC is medicinal chemistry in its broadest 
sense. DDC offers compound discovery by high throughput screening (HTS); computational chemistry for in 
silico virtual screening and modeling; chemical informatics to identify and prioritize compounds; chemical 
synthesis of potent, selective, and pharmacologically viable compounds; and analytical chemistry to support 
UWCCC clinical trials with pharmacokinetic (PK) and pharmacodynamic (PD) assays. Aim 1 is to advance 
UWCCC member drug development research by providing broad medicinal chemistry expertise and 
infrastructure encompassing discovery, synthetic chemistry, computational chemistry, analytical chemistry, and 
pharmacology of chemoprevention and anticancer agents. DDC staff advise UWCCC members in all aspects 
of experimental design and data interpretation. The highly-skilled and experienced staff are experts in the use 
of state-of-the-art equipment for microwave-facilitated organic synthesis, analytical and preparative HPLC, 
mass spectrometry, combi-flash chromatography, tip-less and tip-based liquid handling robotics, assay 
quantification in 96 through 1536-well plate readers, and high throughput computing. Aim 2 is to support 
clinical trials conducted at UWCCC by providing analytical chemistry expertise needed to evaluate the 
pharmacokinetic and pharmacodynamic properties of study drugs and to provide patient sample storage with 
robust and secure database documentation of all samples. DDC staff are tightly coordinated with the clinical 
trial enterprise at UWCCC including participation in the Cancer Therapy Discovery and Development (CTD2) 
group and the Disease Oriented Teams to support UWCCC members with assays for drug concentrations and 
biomarkers on any clinical substrate and storage of study samples from clinical trials. In the current funding 
period, the core provided support for 394 UWCCC studies. Aim 3 is to train UWCCC members, their staff, and 
students in drug development processes and the productive application of state-of-the-art, well-maintained 
equipment to their specific research goals and provide 24/7 access to this drug development focused 
infrastructure. Impact on UWCCC: The DDC has supported the research of 128 unique UWCCC members 
during the current funding cycle and is well-staffed and equipped to meet the future drug development needs of 
UWCCC members. Continued support from the CCSG will enable highly experienced DDC staff scientists to 
invest time and expertise in consulting with UWCCC members on future projects and on advancing current 
promis...

## Key facts

- **NIH application ID:** 10147668
- **Project number:** 5P30CA014520-47
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **Principal Investigator:** TIMOTHY S BUGNI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $219,105
- **Award type:** 5
- **Project period:** 1997-04-25 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10147668

## Citation

> US National Institutes of Health, RePORTER application 10147668, Drug Development Core Shared Resource (5P30CA014520-47). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10147668. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*